Latest studies
- AuthorisedTherapeutic exploratory (Phase II)
A multicentre, prospective, open-label study with [68Ga]Ga-ABY-025 PET-imaging to characterize HER2-expression and explore the therapy-predictive value for HER2-antibody drug conjugates in patients with metastatic breast cancer (HER2-Ex PET)
This study looks at a new special scan for breast cancer to see how HER2 protein levels affect treatment. It uses a new drug called Enhertu to treat metastatic breast cancer and aims to find out if the scan can predict how well the treatment will work.
Breast CancerSweden - RecruitingNA
Improving CRT Outcome With Non-Invasive Cardiac Mapping
This study looks at a new way to place a special device (CRT) for people with heart failure. It compares standard placement with a new method using a special mapping system to see if it improves how well the treatment works.
Heart Failure With Reduced Ejection FractionSweden - AuthorisedPhase II and Phase III (Integrated)
An Operationally Seamless Phase 2/3, Randomized, Active -Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of GS-1720 in Combination With GS-4182 Versus Biktarvy in Virologically Suppressed People With HIV-1
This study is testing a new weekly pill for HIV to see if it's as good as a daily pill people already take. It's for adults whose HIV is already under control. We want to check how safe and effective the new weekly treatment is.
HIV-1 InfectionSweden - RecruitingPHASE3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
This study looks at a new medicine, Maridebart cafraglutide, for people with heart failure and obesity. It aims to see if the medicine can reduce heart-related problems like hospital stays, improve symptoms, and help people live longer, alongside their usual heart failure care.
Heart Failure With Preserved Ejection FractionHeart Failure With Mildly Reduced Ejection FractionObesitySweden - RecruitingPHASE3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
This study looks at a new medicine, abelacimab, for people with an irregular heartbeat (atrial fibrillation) who can't take usual blood thinners. It compares abelacimab to a dummy medicine to see if it can prevent strokes.
Atrial Fibrillation (AF)Sweden - RecruitingPHASE2
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
This study is testing a new medicine, GSK4532990, for people aged 18-70 with liver damage caused by alcohol. We want to see if it's safe and if it helps the liver. Some people will get the medicine, others a dummy pill.
Liver Diseases, AlcoholicSweden - Active not recruitingPHASE3
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
This study is looking at a new drug, quizartinib, combined with standard chemotherapy for adults recently diagnosed with a specific type of leukaemia called AML. We want to see if this combination improves treatment outcomes compared to chemotherapy alone.
LeukemiaSweden - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Thyroid Eye Disease
This study is looking at a new medicine called Vyvgart for people with Thyroid Eye Disease. It aims to see if the medicine can help reduce bulging eyes and improve eye health, compared to a dummy medicine, over 24 weeks.
Thyroid Eye Disease (TED)Sweden - RecruitingNA
Colectomy Reconstruction for Ulcerative Colitis, Ileorectal Anastomosis vs Ileal Pouch-Anal Anastomosis in Ulcerative Colitis.
This study compares two common surgeries to reconnect your gut after removing most of your large bowel for Ulcerative Colitis. It aims to see which one, an ileal pouch or an ileorectal anastomosis, offers the best quality of life, satisfaction, and fewer complications for patients in the UK.
Ulcerative ColitisInflammatory Bowel DiseasesIleostomy - StomaSweden - Enrolling by invitationNA
Optical Coherence Tomography in Acute Vessel Evaluation
This study compares two ways to help people having a heart attack: one uses standard X-rays, the other uses a special camera called OCT. We want to see if the OCT camera leads to better results for patients.
Ischemic Heart DiseaseIschemic Coronary Artery DiseaseACS (Acute Coronary Syndrome)Sweden - Ongoing, recruitingPhase II and Phase III (Integrated)
A Phase 2/3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP 363856 in the Treatment of Adults with Generalized Anxiety Disorder
This study is looking at a new medicine called Ulotaront for adults with generalised anxiety disorder. We want to see if it helps reduce anxiety and if it's safe to use. Some people will get the new medicine, and others will get a dummy pill.
generalised anxiety disorderSweden - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Eventdriven, Multi-center Phase 2 Clinical Outcome Trial of Prevention of Arteriovenous Graft Thrombosis and Safety of MK-2060 in Patients With End Stage Renal Disease Receiving Hemodialysis
This study is testing a new medicine, MK-2060, to see if it can stop blood clots forming in special tubes (grafts) used for kidney dialysis. We want to know if it's safe and if it works better than a dummy medicine (placebo) for people with serious kidney disease.
Prevention of arteriovenous graft thrombosisSweden - Ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PARALLEL AND PLACEBO-CONTROLLED SINGLE AND MULTIPLE ASCENDING DOSE TRIAL INVESTIGATING SAFETY, TOLERABILITY AND PHARMACOKINETICS OF LIB-01 IN HEALTHY PARTICIPANTS
This study is testing a new medicine, LIB-01, for erectile dysfunction in healthy men. It's the first time this medicine is being given to people. Researchers want to see if it's safe, how well the body handles it, and what side effects it might have.
Erectile dysfunctionSweden - Active not recruitingPHASE3
Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A
This study is looking at a new medicine called efanesoctocog alfa (BIVV001) for people with haemophilia A. It aims to see if it's safe and effective over a long time in preventing and treating bleeds, improving joint health and quality of life.
Hemophilia ASweden - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Randomized Clinical Study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Physician’s Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008)
This study is testing a new combination medicine (MK-4280A) against standard chemotherapy for people with Hodgkin Lymphoma that has come back or not responded to previous treatments. We want to see if the new medicine can stop the cancer from growing for longer.
Relapsed or Refractory Classical Hodgkin LymphomaSweden - AuthorisedPhase II and Phase III (Integrated)
An International Prospective Study in Children Older than 3 to 5 Years with Clinically Standard-Risk Medulloblastoma with Low-Risk Biological Profile (PNET 5 MB – LR and PNET 5 MB – WNT-HR), average-risk biological profile (PNET 5 MB -SR), or TP53 mutation, and registry for MB ocurring in the context of genetic predisposition
This study is for children aged 3-18 with a type of brain tumour called medulloblastoma. It looks at different ways to treat the tumour, including various chemotherapy drugs, to find the most effective and safest options for different types of medulloblastoma, aiming to improve chances of recovery and quality of life.
MedulloblastomaSweden - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
This study aims to find the best dose of BI 907828 (brigimadlin) in patients with different types of advanced cancer (solid tumors)
This study is looking for the best dose of a new medicine called BI 907828 (brigimadlin) for people with advanced cancers that have grown or spread. It's an early-stage study to understand how the medicine works in the body.
Advanced or metastatic solid tumorsSweden - AuthorisedTherapeutic exploratory (Phase II)
Randomized Open Label Trial Evaluating Efficacy and Safety of Intravenous Immunoglobulin (IVIg, Privigen) as Add-on to SoC Versus SoC Alone for Coronavirus Disease 2019 (COVID-19) in Patients with Severely Impaired B-cell Function
This study is testing a medicine called Privigen for people with COVID-19 who have a weakened immune system. It aims to see if adding Privigen to standard care helps them recover better than standard care alone.
COVID-19 and Severely Impaired B-cell FunctionSweden - Active not recruitingPHASE2
A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM
This study is testing two medicines, eplontersen and ALXN2220, to see if they are safe and help adults with a heart condition called ATTR-CM. Participants will take eplontersen along with either ALXN2220 or an inactive substance (placebo).
Transthyretin Amyloid Cardiomyopathy (ATTR-CM)Sweden - Active not recruitingPHASE3
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
This study looks at a new combination of medicines for postmenopausal women with a certain type of breast cancer. It tests if abemaciclib with standard hormone therapy works better than hormone therapy alone.
Breast CancerSweden - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
This study is testing a new medicine, GEN3014, for people with multiple myeloma or other blood cancers that have come back or not responded to previous treatments. It aims to see if the medicine is safe and how well it works.
Relapsed or Refractory Multiple Myeloma (RRMM)Diffuse Large B Cell Lymphoma (DLBCL)Acute Myeloid Leukemia (AML)Sweden - RecruitingPHASE3
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
This study is looking into a new medication called AZD0780. It aims to see if this medicine can lower the risk of serious heart problems like heart attacks or strokes in people who have already had them, or in those at high risk of having one for the first time.
Cardiovascular DiseaseSweden - RecruitingPHASE1, PHASE2
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
This study is testing a new light-based treatment for men with prostate cancer that has come back. It uses a special light system called SpectraCure P18 and a drug called verteporfin to see if it's safe and helps shrink the cancer.
Recurrent Prostate CancerSweden - RecruitingPHASE2
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
This study is looking into a new medicine, calderasib, to treat certain advanced cancers. Researchers want to see if it can shrink these cancers, either alone or with another medicine called cetuximab, in people whose cancers have a specific genetic change (KRAS G12C mutation).
Neoplasm MalignantSweden - Active not recruitingPHASE3
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
This study looks at a new way to treat a type of leukaemia (blood cancer) called B-cell precursor acute lymphoblastic leukaemia (ALL) in older adults. It compares a drug called Blinatumomab combined with gentler chemotherapy against the usual chemotherapy treatment to see which works best.
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)Sweden - RecruitingPHASE3
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
This study looks at a new treatment called Pumitamig for advanced non-small cell lung cancer that hasn't been treated before. It compares Pumitamig to an existing treatment, Pembrolizumab, in people whose cancer cells have a high level of a specific marker called PD-L1.
Non-Small Cell Lung Cancer (NSCLC)Sweden - Active not recruiting
FARAPULSE Workflow Assessment Registry
This study looks at how clinics use a new treatment called Pulsed Field Ablation (using the FARAPULSE system) for an irregular heartbeat called Atrial Fibrillation. It aims to find the best ways to use this treatment and improve patient care.
Atrial Fibrillation (AF)Sweden - Recruiting
Patient Retrospective Outcomes (PRO)
This study looks back at anonymous medical records of adults with long-lasting pain. It compares how well different treatments worked, including those from Boston Scientific, to help doctors understand what works best for patients.
Chronic PainSweden - RecruitingPHASE2, PHASE3
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
This study is testing a new medicine, elenestinib, for a rare blood condition called indolent systemic mastocytosis. It compares the new medicine to a dummy pill (placebo) to see if it helps reduce symptoms that current treatments aren't fully controlling.
Indolent Systemic MastocytosisSmoldering Systemic MastocytosisSweden - Ongoing, recruitingTherapeutic confirmatory (Phase III)
C4601003 - A PHASE 3, MULTICENTER, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY, AND LOT CONSISTENCY OF A 6-VALENT OSPA-BASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS ≥5 YEARS OF AGE
This study is testing a new vaccine to see if it can prevent Lyme disease. Researchers want to find out how well it works, if it's safe for people aged 5 and older, and if it causes any side effects. They are also checking how the body reacts to the vaccine.
Active immunization against Lyme diseaseSweden - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25) – Substudy A – Relapsed/Refractory Waldenstrom Macroglobulinemia
This study is testing a new cell therapy called Tecartus for adults in the UK with a rare blood cancer called Waldenstrom Macroglobulinemia. It's for people whose cancer has come back or hasn't responded to previous treatments. We want to see how well it works and if it's safe.
Relapsed/Refractory Waldenstrom Macroglobulinemia (WM)Sweden - Active not recruitingPHASE3
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
This study is looking into a new combination treatment for a type of breast cancer called triple-negative breast cancer (TNBC) that has spread or is advanced. It combines a new drug, Capivasertib, with a common chemotherapy, Paclitaxel, to see if it works better than just Paclitaxel alone.
Triple Negative Breast NeoplasmsSweden - RecruitingPHASE3
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
This study is looking at two different treatments, pumitamig and durvalumab, for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that can't be removed by surgery. It's for patients who have already had chemotherapy and radiation.
Non-small Cell Lung Cancer (NSCLC)Sweden - RecruitingPHASE3
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This study compares two medicines, BGB-16673 and pirtobrutinib, for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) when previous treatments haven't worked well enough. It aims to see which medicine is safer and more effective.
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaSweden - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab versus Risankizumab in the Treatment of Participants with Moderately to Severely Active Crohn’s Disease
This study compares two existing medicines, Guselkumab and Risankizumab (also known as Skyrizi), for adults with Crohn's disease that is moderate to severe. It aims to see which medicine works better and is safer over time to help people feel much better.
Moderately to Severely Active Crohn’s DiseaseSweden - AuthorisedTherapeutic use (Phase IV)
Evaluation of ALLERgen Specific Vaccination of DOG Allergic Patients in Swedish Practice - ALLERDOG SWEDEN
This study is looking at how well a treatment called Alutard SQ Dog works for people with dog allergy. It checks if the treatment reduces sneezing, itchy eyes, and other symptoms after being around dogs for one year.
Allergic rhinitis due to dog allergySweden - Active not recruitingPHASE2
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
This study looks at a new medicine called sotatercept for a specific type of high blood pressure in the lungs (Cpc-PH) linked to heart failure. It's for people who were in a previous study to see how the medicine works long-term and if it's safe.
Hypertension, PulmonarySweden - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
PET study of changes in [11C]AZ14132516 uptake following administration of AZD7798 to healthy participants and patients with Crohn’s disease
This study is looking at a new medicine for Crohn's disease. We want to see how a special scan changes before and after taking the medicine, both in healthy people and those with Crohn's. This helps us understand how the medicine works.
Crohn's DiseaseSweden - Active not recruiting
The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema
The SPECTRUM Study is looking at how well a new eye medicine called aflibercept 8 mg works for vision problems caused by wet AMD or diabetic macular oedema. Researchers will collect information from patients who are already prescribed this medicine by their doctor.
Visual ImpairmentNeovascular Age-related Macular Degeneration (nAMD)Diabetic Macula Edema (DME)Sweden - Active not recruitingPHASE3
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
This study is testing a new medicine, tulisokibart, for people with moderate to severe ulcerative colitis. It aims to see if the medicine can help people feel better and stay in remission, compared to a dummy medicine, both in the short and long term.
Ulcerative ColitisSweden - Active not recruitingPHASE3
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
This study is testing a new medicine, Amlitelimab, for moderate-to-severe eczema in people aged 12 and over. It's looking at how well different doses work and if they're safe, compared to stopping treatment.
Dermatitis AtopicSweden - Enrolling by invitationPHASE3
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
This study looks at a new medicine called efgartigimod for people with certain muscle conditions like myositis. It's for adults who were in a previous study, to see if the medicine is safe and helpful over a long time.
MyositisActive Idiopathic Inflammatory MyopathyDermatomyositisPolymyositisSweden - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A5481092: PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS
This study looks at new drug combinations for children with specific types of cancer (Ewing sarcoma or neuroblastoma) that have come back or not responded to previous treatment. It tests how safe and effective these combinations are.
recurrent/refractory Ewing sarcoma, recurrent or refractory neuroblastomaSweden - Active not recruitingPHASE3
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
This study looks at a new drug, astegolimab, for people with COPD who have flare-ups often. It compares the new drug to a dummy treatment (placebo) to see if it's safe and helps improve their breathing and reduce flare-ups.
Chronic Obstructive Pulmonary Disease (COPD)Sweden - AuthorisedTherapeutic confirmatory (Phase III)
Immediate versus delayed insertion of intrauterine contraception at the time of medical abortion- An open-label, randomized, multicenter study
This study compares when to fit an intrauterine contraceptive (IUC), like a coil, after a medical abortion. It looks at whether fitting it straight away or later works best for women.
Post medical abortion contraceptionSweden - Ongoing, recruitingTherapeutic confirmatory (Phase III)
(21181) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of the central nervous system (CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs)
This study is testing a new, lower-dose contrast dye called gadoquatrane for MRI brain scans. It wants to see if it's as good and safe as current higher-dose dyes at showing problems in the brain and spinal cord, like tumours or inflammation.
Contrast enhancement in magnetic resonance imaging for assessment of central nervous system pathologySweden - RecruitingPHASE3
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
This study looks at a new medicine, Baxdrostat, combined with an existing one, Dapagliflozin, for people with long-term kidney disease and high blood pressure. It aims to see if this combination can help protect the kidneys and heart better than Dapagliflozin alone.
Chronic Kidney Disease and HypertensionSweden - Active not recruitingPHASE3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
This study compares a new treatment called Sacituzumab Tirumotecan with standard care for recurrent or metastatic cervical cancer. It aims to see if the new treatment improves how long people live when current treatments aren't enough.
Cervical CancerSweden - RecruitingPHASE3
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
This study is looking at two new drug combinations for adults newly diagnosed with Chronic Lymphocytic Leukemia (CLL). It compares sonrotoclax plus zanubrutinib with venetoclax plus acalabrutinib to see which is more effective and safer for treating this type of blood cancer.
Chronic Lymphocytic LeukemiaSweden - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of OG-6219 in 3 Dose Levels, in Women 18 to 49 Years of Age with Moderate to Severe Endometriosis-related Pain
This study is testing a new tablet, OG-6219, for women aged 18-49 experiencing moderate to severe pain from endometriosis. It will compare different doses against a dummy pill to see how well it works and if it's safe.
Endometriosis related painSweden